NCT00409656.

Trial name or title	Prospective, randomised trial of basiliximab (Simulect) in the prophylaxis of high‐risk keratoplasty patients
Methods	Allocation: randomised Control: active control Endpoint classification: efficacy study Intervention model: parallel assignment Masking: open label Primary purpose: prevention
Participants	Inclusion criteria: high‐risk keratoplasty Exclusion criteria: normal‐risk keratoplasty Age minimum: N/A Age maximum: N/A Gender: both
Interventions	Basiliximab
Outcomes	Primary outcome: graft rejection Secondary outcome: clear graft survival
Starting date	December 2003
Contact information	Thomas Reinhard, MD, Prof. (http://clinicaltrials.gov/show/NCT00409656)
Notes